Clinical Trial Update: Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating post-radiation adjuvant temozolomide chemotherapy for residue low-grade glioma; recruiting status suggests ongoing efficacy assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Oligodendroglioma

Drugs mentioned

• Temozolomide (Temozolomide)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Astrocytoma, Oligodendroglioma | Phase 3 | Status: RECRUITING